Although the underlying mechanisms may differ, the ultimate activation of NRF2's target genes, including detoxifying enzymes, antioxidant proteins, and drug transporters, confers cancer resistance to anti-cancer drugs. This evidence concerns the gene NFE2L2 and cancer.